A dose optimization study of durvalumab (anti-PDL1) plus tremelimumab (anti-CTLA4) for patients with non-small-cell lung cancer revealed an increasing trend of T cell proliferation and activation in peripheral blood with increasing tremelimumab dosage.
← all excerpts
Translational research on drug development and biomarker discovery for hepatocellular carcinoma.
1
—
—